News | November 05, 2021
Prime Therapeutics to list Semglee and Insulin Glargine
Biocon Biologics and Viatris co-developed the products
Biocon Biologics and Viatris co-developed the products
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
The centralized marketing authorization granted by the EC is valid in all EU Member
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Subscribe To Our Newsletter & Stay Updated
